Nuclear Receptors Conference - Mexico 2018

External Event - 27th Feb to 2nd Mar 2018

New Roles for Nuclear Receptors in Development, Health and Disease

27 Feb 2018 - 02 Mar 2018

Cancun, Mexico


Nuclear Receptors are, physiologically and pharmacologically, a critical superfamily of transcription factors. They drive key processes at every stage from development and reproduction to ageing and cancer. They are critical determinants of everyday health via their roles in metabolism and circadian rhythms. Nuclear receptors allow external factors to influence cellular pathways and the fact that many bind and are activated by small molecules means they represent highly druggable targets; currently, 13% of FDA-approved drugs target nuclear receptors.

This meeting will address the new roles and novel crosstalk mechanisms that are emerging for many of the 48 human nuclear receptors, in health and disease. For example, it has long been known that the estrogen receptor drives progression of breast cancer, and patients with estrogen receptor-positive disease are treated using antiestrogens or aromatase inhibitors to inhibit estrogen signalling. Now however, it is apparent that the androgen receptor can in some cases drive breast cancer progression and is a therapeutic target, resulting in clinical trials for androgen receptor-targeting therapies in advanced breast cancer. The androgen receptor, itself long the main therapeutic target in prostate cancer, is emerging as a key player in metabolic disease, while conversely other nuclear receptor including the glucocorticoid receptor and several orphan nuclear receptors are implicated in prostate cancer progression. Meanwhile, given the impact of many nuclear receptors on the central nervous system, it is unsurprising that they are being explored in the context of neurological disorders and depression. Thus there is wide scope for re-purposing of licensed drugs and development of new NR-targeting therapies for a host of conditions and diseases.

Crosstalk between nuclear receptors and other fundamental processes is another exciting expanding area that will also be covered. DNA damage repair pathways are inextricably linked to steroid signalling via transcriptional processes, with implications for drug combinations in several diseases. Hitherto unsuspected roles of nuclear receptors in epigenetic control and the processing and function of non-coding RNAs opens up to capacity of this superfamily to further means of impacting on development and normal functioning, but also on disease development. 

This unique meeting will bring together many of the leading figures in nuclear receptor research from across the globe, to discuss emerging roles and their implications for health and disease – and both human and drug development – in an intimate meeting that will generate meaningful idea exchange and interaction that will help to further shape this influential field.

Key Sessions

Further emerging roles for nuclear receptors in cancer

Structural insights into nuclear receptor function and crosstalk

Nuclear receptors’ role in epigenetic regulation and non coding RNA

Nuclear receptors and DNA damage

Nuclear receptors and cell cycle

Nuclear receptors in metabolism/metabolic disease

Nuclear receptors in the CNS

Target Audience

Scientists and Clinician Scientists at a range of levels from postdoctoral and up: Principal Investigators, Junior Team Leaders, Research Fellows. Ambitious postgraduate students in the field will also be encouraged to attend.

Relevant specialties are wide-ranging, reflecting the importance of nuclear receptors in many aspects of health and disease. These include Endocrinology, Oncology, Paediatrics, Urology, Gynaecology, Obstetric Medicine, Neuroscience, Cardiology.

Invited Speakers

Suzanne Conzen (The University of Chicago)
Theresa Hickey (The University of Adelaide)
Lee Kraus (The University of Texas Southwestern Medical Center)
Luca Magnani (Imperial College London)
Sebastiaan H. Meijsing (Max Planck Institute for Molecular Genetics) 
David D. Moore (Baylor College of Medicine)
Eric Ortlund (Emory University)
Eva Estebanez Perpiña (University of Barcelona)
David Ray (The University of Manchester)
Kristina Schoonjans (EPFL)
Carlie J.M. de Vrie (University of Amsterdam)
Wilbert Zwart (Netherlands Cancer Institute)

For more information visit







< Back to Events